Voltar para o dashboard

EB1 (USCIS), Isabella Harumi Yonehara Noma, 3309

Receipt notice ok

CompleteEditar exhibit
Abrir PDF atual

Edite e gere a versão final no editor.

Resumo

Documentos vinculados
115
Incluídos no exhibit
0
Ignorados pelo gerador
115
Arquivos a processar
0

Nenhum documento entraria no exhibit

Confira a lista de ignorados abaixo e ajuste o status, exhibit fields ou attachments no Airtable antes de gerar.

Ignorados pelo gerador (115)

Estes documentos não entrarão no PDF até que sejam corrigidos.

DocumentoStatusRazão
Form G-1450, Authorization for Credit Card Transaction of $715.00 towards I-140 filing fee.
Forms and Cover
Received and validSem Client files e sem Translation files
Form G-1450, Authorization for Credit Card Transaction of $300 towards Asylum Program fee.
Forms and Cover
Received and validSem Client files e sem Translation files
Petition Cover Sheet
Forms and Cover
Received and validSem Client files e sem Translation files
G-1145, E-Notification of Application/Petition Acceptance
Forms and Cover
Received and validSem Client files e sem Translation files
Form G-28: Notice of Entry of Appearance as Attorney or Accredited Representative
Forms and Cover
Received and validSem Client files e sem Translation files
Form I-140: Immigrant Petition for Alien Worker
Forms and Cover
Received and validSem Client files e sem Translation files
Cover Letter
Forms and Cover
Received and validSem Client files e sem Translation files
A.1. Beneficiary’s Personal Statement
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
A.2. Dr. Noma’s Curriculum Vitae
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
A.3. Bachelor’s Degree in Biomedical Sciences
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
A.4. Postgraduate Certificate in Biomedical Engineering
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
A.5. Master’s Degree in Health Sciences
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
A.6. Doctorate in Sciences
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
A.7. Postdoctoral Fellowship
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
A.8. MBA in Data Science and Analytics
Exhibit A. Evidence on Dr. Noma
Received and valid"Exhibit with translation only" mas sem Translation files
B.1. Award certificate/confirmation of Poster Award / Honorable Mention for: “Targeting Peroxiredoxin 2 as a potential treatment for NRAS mutated metastatic melanoma,” Symposium commemorating the 50th Anniversary of the Postgraduate Program in Pharmacy – Pathophysiology and Toxicology, Faculty of Pharmaceutical Sciences, University of São Paulo (FCF/USP), São Paulo, Brazil (November 2022).
Exhibit B. Evidence that the beneficiary was the recipient of the awards
Received and validSem Client files e sem Translation files
B.2. Photograph(s) of Dr. Noma presenting her poster at the Symposium
Exhibit B. Evidence that the beneficiary was the recipient of the awards
Received and validSem Client files e sem Translation files
B.3. Official Symposium Activity Report (November 2022) for the Symposium commemorating the 50th Anniversary of the Postgraduate Program in Pharmacy – Pathophysiology and Toxicology (FCF/USP), documenting the Symposium structure, the poster sessions and faculty evaluation process, and the official listing of awardees including Dr. Noma’s Honorable Mention
Exhibit B. Evidence that the beneficiary was the recipient of the awards
Received and valid"Exhibit with translation only" mas sem Translation files
B.4. Award letter/notice from CNPq granting Dr. Noma the Postdoctoral Fellowship Abroad, including award period and benefits
Exhibit B. Evidence that the beneficiary was the recipient of the awards
Received and validSem Client files e sem Translation files
B.5. Background information on CNPq establishing CNPq as a Brazilian federal government science and research funding agency
Exhibit B. Evidence that the beneficiary was the recipient of the awards
Received and validSem Client files e sem Translation files
B.6. CNPq Selection and Judging Requirements for scholarships/fellowships abroad, showing the formal, multi-stage, comparative merit-review and ranking process
Exhibit B. Evidence that the beneficiary was the recipient of the awards
Received and validSem Client files e sem Translation files
C.1. BJPS ScholarOne notice confirming account creation and addition to the reviewer database (April 5, 2024).
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
C.2. Formal invitation from the Associate Editor of the Brazilian Journal of Pharmaceutical Sciences to review Manuscript ID BJPS-2024-0245 (April 5, 2024)
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
C.3. Editorial reminder from the Brazilian Journal of Pharmaceutical Sciences confirming Dr. Noma’s active peer review assignment (April 19, 2024)
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
C.4. Completed Peer Review Report for Manuscript ID BJPS-2024-0245, including technical ratings, editorial recommendation, and substantive comments to the author (April 21, 2024)
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
C.5. Official Certificates of Service as Ad Hoc Abstract Reviewer for the VI and VII International Meetings of Biosciences and Physiopathology (2019–2020)
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
C.6. Reviewer orientation and instruction communications from the Organizing Committee of the VI International Meeting of Biosciences and Physiopathology (September 2019)
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
C.7. Email acknowledgment from the Organizing Committee confirming the final round of abstract corrections for the VII International Meeting of Biosciences and Physiopathology (August 2020)
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
C.8. Institutional Statement from the Coordinator of the Postgraduate Program in Biosciences and Physiopathology (PBF) confirming Dr. Noma’s evaluative responsibilities and contributions to scientific quality control (December 15, 2025)
Exhibit C. Evidence that the beneficiary participated as a judge of the work of others in the field of scientific research
Received and validSem Client files e sem Translation files
D.1. "Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers," IHY Noma et al., Biomedicine & Pharmacotherapy (2024)
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.2. Recommendation letter from Dr. Jérémie Nsengimana, PhD (Newcastle University, UK), confirming the "transformative" nature and independent validation of the PRDX2 discovery
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.3. "Modeling melanoma heterogeneity in vitro: redox, resistance and pigmentation profiles," LAC Carvalho, IHY Noma et al., Antioxidants (2024).
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.4. "2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFI-Resistant Melanoma," YA Franco et al. (including IHY Noma), IJMS (2023).
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.5. Recommendation letter from Prof. Silvia Berlanga de Moraes Barros, PhD (University of São Paulo), explaining the significance of the heterogeneity and resistance research
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.6. Recommendation letter from Dr. Patrícia Abrão Possik, PhD (Brazilian National Cancer Institute/INCA), highlighting the translational impact of the redox and resistance findings
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.7. University of São Paulo (USP) Postdoctoral Program Completion Certificate (translated), explicitly titled project: “The Role of HDAC8 in UVR-Driven Melanoma Initiation,” documenting completion and scope of the HDAC8/UVR research
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.8. Recommendation letter from Prof. Silvya Stuchi Maria-Engler, PhD (University of São Paulo), corroborating the impact of the HDAC8/UV-induced melanoma discovery
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.9. “Association of high risk Human Papillomavirus and Ureaplasma parvum co infections with increased risk of low grade squamous intraepithelial cervical lesions,” Asian Pacific Journal of Cancer Prevention (2021).
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.10. Recommendation letter from Prof. Marcia Edilaine Lopes Consolaro, PhD (State University of Maringá/UEM), documenting Dr. Noma’s original Master’s research and the first-published evidence linking high-risk HPV and Ureaplasma parvum co-infections to cervical lesion risk
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.11. “14 Week exercise training modifies the DNA methylation levels at gene sites in non Alzheimer’s disease women aged 50 to 70 years,” Experimental Gerontology (2024).
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.12. “14 weeks combined exercise epigenetically modulated 118 genes of menopausal women with prediabetes,” Frontiers in Endocrinology (2022).
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.13. Recommendation letter from Ana Campa, PhD (Full Professor, Faculty of Pharmaceutical Sciences, University of São Paulo), corroborating the originality and technical significance of the PRDX2/EMT discovery, the HPV/Ureaplasma co-infection findings, and the impact of the exercise-induced epigenetic research
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.14. Google Scholar citation report for Dr. Noma as of February 26, 2026, documenting 127 total citations, an h-index of 7, and an i10-index of 6
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
D.15. Google Scholar citation report for Dr. Noma as of October 2025, documenting 97 total citations, an h-index of 6, and an i10-index of 5
Exhibit D. Evidence of the original scientific contributions of major significance in the field
Received and validSem Client files e sem Translation files
E.1. Dr. Noma’s Curriculum Vitae (Lattes). Contains the complete list of all scholarly articles authored by Dr. Noma, including journal titles, years, co authors, and citation counts in Web of Science and Scopus
E. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media
Received and validSem Client files e sem Translation files
E.2. Web of Science (Clarivate) Researcher Profile. Independent report from Clarivate Analytics verifying 20 publications indexed in the prestigious Web of Science Core Collection, 146 total citations, and an h-index of 6
E. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media
Received and validSem Client files e sem Translation files
E.3. SCImago "How We Work" Methodology Report. Documentation explaining the scientific validity of SCImago indicators, its partnership with the Scopus (Elsevier) database, and the peer-reviewed research supporting its ranking system. This establishes the reliability of the journal metrics used throughout this petition
E. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media
Received and validSem Client files e sem Translation files
E.4.1. “Peroxiredoxin 2 represses NRAS mutated melanoma cell invasion by modulating EMT markers,” Biomedicine & Pharmacotherapy (2024)
E.4. Evidence of publication in Biomedicine & Pharmacotherapy (2024)
Received and validSem Client files e sem Translation files
E.4.2. SCImago journal profile for Biomedicine & Pharmacotherapy showing SJR 2024: 1.775, Q1 ranking, H index 169, coverage in Medicine and Pharmacology, and indexing in Scopus/Web of Science
E.4. Evidence of publication in Biomedicine & Pharmacotherapy (2024)
Received and validSem Client files e sem Translation files
E.5.1. “Modeling melanoma heterogeneity in vitro: redox, resistance, and pigmentation profiles,” Antioxidants (2024)
E.5. Evidence of publication in Antioxidants (2024)
Received and validSem Client files e sem Translation files
E.5.2. SCImago journal profile for Antioxidants showing SJR 2024: 1.484, Q1 status, H index 133, MDPI publisher information, and subject categories in Biochemistry, Genetics and Molecular Biology
E.5. Evidence of publication in Antioxidants (2024)
Received and validSem Client files e sem Translation files
E.6.1. “14 weeks combined exercise epigenetically modulated 118 genes of menopausal women with prediabetes,” Frontiers in Endocrinology (2022)
E.6. Evidence of publication in Frontiers in Endocrinology (2022)
Received and validSem Client files e sem Translation files
E.6.2. SCImago profile for Frontiers in Endocrinology (SJR 2024: 1.472; Q1; H index 138; scope describing rigorous peer review and a global clinical/endocrine audience)
E.6. Evidence of publication in Frontiers in Endocrinology (2022)
Received and validSem Client files e sem Translation files
E.7.1. “DNA methylation signatures of arsenic exposure and obesity,” Environmental Epigenetics (2025).
E.7. Evidence of publication in Environmental Epigenetics (2025)
Received and validSem Client files e sem Translation files
E.7.2. Evidence of indexing and professional status (publisher or database pages confirming peer review and inclusion in major scientific databases such as Web of Science/Scopus)
E.7. Evidence of publication in Environmental Epigenetics (2025)
Received and validSem Client files e sem Translation files
E.8.1. “14 Week exercise training modifies the DNA methylation levels at gene sites in non Alzheimer’s disease women aged 50 to 70 years,” Experimental Gerontology (2024)
E.8. Evidence of publication in Experimental Gerontology (2024)
Received and validSem Client files e sem Translation files
E.8.2. SCImago (or equivalent) profile confirming Experimental Gerontology’s Q1 ranking in Aging/Gerontology and indexing in Web of Science and Scopus
E.8. Evidence of publication in Experimental Gerontology (2024)
Received and validSem Client files e sem Translation files
E.9.1. “Eight weeks of physical training decreases 2 years of DNA methylation age of sedentary women,” Research Quarterly for Exercise and Sport (2023)
E.9. Evidence of publication in Research Quarterly for Exercise and Sport (2023)
Received and validSem Client files e sem Translation files
E.9.2. SCImago profile for Research Quarterly for Exercise and Sport showing Q1 status (SJR ≈ 0.78), long standing coverage in sports sciences, and Scopus indexing
E.9. Evidence of publication in Research Quarterly for Exercise and Sport (2023)
Received and validSem Client files e sem Translation files
E.10.1. “The influence of serum selenium in differential epigenetic and transcriptional regulation of the CPT1B gene in women with obesity.”
E.10. Evidence of publication in Journal of Trace Elements in Medicine and Biology (2023/2024):
Received and validSem Client files e sem Translation files
E.10.2. SCImago or publisher documentation showing the journal’s subject areas (Medicine, Biochemistry), Q1/Q2 ranking, and indexing in Web of Science and Scopus
E.10. Evidence of publication in Journal of Trace Elements in Medicine and Biology (2023/2024):
Received and validSem Client files e sem Translation files
E.11.1. “Gene signatures of autopsy lungs from obese patients with COVID 19,” Clinical Nutrition ESPEN (2021).
E.11. Evidence of publication in Clinical Nutrition ESPEN (2021):
Received and validSem Client files e sem Translation files
E.11.2. SCImago profile for Clinical Nutrition ESPEN (SJR 2024: 0.805; Q2 in Nutrition and Dietetics and Endocrinology/Metabolism; H index 46; official ESPEN journal; indexed in Scopus/Web of Science).
E.11. Evidence of publication in Clinical Nutrition ESPEN (2021):
Received and validSem Client files e sem Translation files
E.12.1. “Sample preparation to bioinformatics analysis of DNA methylation: association strategy for obesity and related trait studies,” Journal of Visualized Experiments (2022)
E.12. Evidence of publication in Journal of Visualized Experiments (JoVE) (2022)
Received and validSem Client files e sem Translation files
E.12.2. SCImago profile for Journal of Visualized Experiments (SJR 2024: 0.431; Q2; H index 141; scope in novel and gold standard research methodologies, indexed in Scopus/Web of Science).
E.12. Evidence of publication in Journal of Visualized Experiments (JoVE) (2022)
Received and validSem Client files e sem Translation files
E.13.1. “Association of high risk Human Papillomavirus and Ureaplasma parvum co infections with increased risk of low grade squamous intraepithelial cervical lesions,” Asian Pacific Journal of Cancer Prevention (2021)
E.13. Evidence of publication in Asian Pacific Journal of Cancer Prevention (APJCP) (2021):
Received and validSem Client files e sem Translation files
E.13.2. SCImago profile for Asian Pacific Journal of Cancer Prevention (SJR 2024: 0.530; H index 98; Q2 in Cancer Research, Q3 in Public Health/Epidemiology; continuous coverage since 2000).
E.13. Evidence of publication in Asian Pacific Journal of Cancer Prevention (APJCP) (2021):
Received and validSem Client files e sem Translation files
E.14.1. “2 Methoxyestradiol 3,17 O,O bis sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFI Resistant Melanoma Cells,” International Journal of Molecular Sciences (2023)
E.14. Evidence of publication in International Journal of Molecular Sciences (2023):
Received and validSem Client files e sem Translation files
E.14.2. SCImago profile for International Journal of Molecular Sciences (SJR 2024: 1.273; Q1; H index 314; broad molecular biology and molecular medicine scope; MDPI; Scopus/Web of Science indexing)
E.14. Evidence of publication in International Journal of Molecular Sciences (2023):
Received and validSem Client files e sem Translation files
E.15.1. “Association between the relative abundance of phyla actinobacteria, vitamin C consumption, and DNA methylation of genes linked to immune response pathways,” Frontiers in Nutrition (2024).
E.15. Evidence of publication in Frontiers in Nutrition (2024):
Received and validSem Client files e sem Translation files
E.15.2. SCImago profile for Frontiers in Nutrition (SJR 2024: 1.12; H-index 84; Q1 in Nutrition and Dietetics; published by Frontiers Media, Switzerland; Scopus-indexed)
E.15. Evidence of publication in Frontiers in Nutrition (2024):
Received and validSem Client files e sem Translation files
E.16. Expert letter from Prof. Marcia Edilaine Lopes Consolaro, PhD attesting to the originality, quality, and influence of Dr. Noma’s scholarly publications and explaining how her articles have guided subsequent research in melanoma, epigenetics, and related fields
E. 16. Evidence that the beneficiary is an author of scholarly articles in the field of science published in professional media
Received and validSem Client files e sem Translation files
F.1. Certificate of Poster Presentation, 19th International Congress of the Society for Melanoma Research (SMR), Edinburgh, Scotland (2022).
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.2. Official Abstract Book, 19th International Congress of the SMR, featuring Dr. Noma’s research (p. 1) (2022)
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.3. Society for Melanoma Research (SMR) "About" and "Congress" Documentation, confirming the Scientific Review Committee and competitive selection process
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.4. Certificate of Presentation and Honorable Mention, FCF/USP 50th Anniversary Symposium (2022)
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.5. Certificate of Presentation, XXII Brazilian Congress of Toxicology (CBTox), organized by the Brazilian Society of Toxicology (SBTox) (2022).
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.6. Brazilian Society of Toxicology (SBTox) "About" Documentation, confirming its affiliation with the International Union of Toxicology (IUTOX).
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.7. Official Proceedings (Anais), III International Symposium of Experimental Pathology (ISEP), featuring Dr. Noma’s research (p. 40) (2019).
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.8. Certificate of Presentation, XXVII Brazilian Congress in Biomedical Engineering (CBEB) (2020).
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.9. Certificate of Presentation, VI International Meeting of Biosciences and Physiopathology - X Symposium of Biosciences Applied to Pharmacy (2019).
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.10. Certificate of Presentation, FCF/USP 50th Anniversary Symposium (2022)
F. Evidence of the display of the Petitioner’s work in the field in Public Exhibitions
Received and validSem Client files e sem Translation files
F.6. Brazilian Society of Toxicology (SBTox) "About" Documentation, confirming its affiliation with the International Union of Toxicology (IUTOX).
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem Client files e sem Translation files
G.1. Postdoctoral Fellow Offer Letter, H. Lee Moffitt Cancer Center and Research Institute (April 28, 2025)
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
G.2. Letter Confirming International Scientific Award Recognition and Critical Role – Dr. Keiran Smalley, Director, Melanoma and Skin Cancer Center of Excellence, Moffitt Cancer Center (November 6, 2025)
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
G.3. Institutional Profile and Economic Impact Documentation, "About Moffitt," confirming NCI Comprehensive Cancer Center designation and $2.4 billion economic impact
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
G.4. National Ranking Reports, Newsweek "America's Best Cancer Hospitals" (2023 and 2024), identifying Moffitt as #1 in Florida and the Southeast and Top 10 in the Nation
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
G.5. Institutional Awards and Recognition Records, confirming Moffitt as a Forbes "America's Best Large Employer" and Becker’s "150 Top Places to Work in Healthcare"
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
G.6. Departmental Overview, "Tumor Microenvironment and Metastasis Department," detailing the specialized research program and elite clinician-scientist faculty
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
G.7. Strategic Partnership Announcements, documenting high-profile oncology collaborations between Moffitt Cancer Center, AstraZeneca, and CMIC Group
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
G.8. Institutional Fellowship Standards, "Postdoctoral Training" and "Become a Moffitt Postdoc," identifying fellows as "outstanding scientific leaders" within the NCI-designated research environment.
Exhibit G. Evidence that the Petitioner has performed in a critical role for an organization of distinguished reputation
Received and validSem Client files e sem Translation files
Previously Approved Dr. Noma’s O-1A Nonimmigrant Petition
Exhibit H. Final Merits Determination
Received and validSem Client files e sem Translation files
Birth Certificate and Corresponding Translation
Exhibit I. Personal Documents
Received and valid"Exhibit with translation only" mas sem Translation files
Passport’s Biometrics Page
Exhibit I. Personal Documents
Received and validSem Client files e sem Translation files
U.S. Visa Page
Exhibit I. Personal Documents
Received and validSem Client files e sem Translation files
I-94
Exhibit I. Personal Documents
Received and validSem Client files e sem Translation files
Marriage certificate and Corresponding Translation
Exhibit I. Personal Documents
Received and valid"Exhibit with translation only" mas sem Translation files
Derivative’s Birth Certificate
Exhibit I. Personal Documents
Received and valid"Exhibit with translation only" mas sem Translation files
Derivative’ s Passport’s Biometrics Page
Exhibit I. Personal Documents
Received and validSem Client files e sem Translation files
Derivative’ s U.S. Visa Page
Exhibit I. Personal Documents
Received and validSem Client files e sem Translation files
Derivative’ s I-94
Exhibit I. Personal Documents
Received and validSem Client files e sem Translation files
reclyIaezYUe5hKGF
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
DNA methylation signatures of arsenic exposure and obesity
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Evidence of participation - Ad hoc reviewer of simple abstract at the VII International Meeting of Biosciences and Physiopathology and XI Symposium of Biosciences Applied to Pharmacy
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Evidence of receipt of lesser nationally or internationally recognized prizes or awards for excellence
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); "Exhibit with translation only" mas sem Translation files
Evidence that you have commanded a salary or other remuneration for services that demonstrates your exceptional ability
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Form I-131: Application for Travel Document
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Form I-485: Application to Register Permanent Residence or Adjust Status
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Form I-693: Report of Medical Examination and Vaccination Record
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Form I-765: Application for Employment Authorization
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); "Exhibit with translation only" mas sem Translation files
Recognition for your achievements and significant contributions to your industry or field by your peers, government entities, professional or business organizations
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
Reviewer - Manuscript ""Dry powder inhalation formulation co-loaded with erlotinib and curcumin for treatment of non-small cell lung cancer."
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
VER ONDE POR, SE TEM LOCAL NA COVER OU NOS PESSOAIS Approval notice: I-797, Notice of Action
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files
VERIFICAR O Q FZR > TLVZ CRIAR UM OTHER ELIGLE EVIDENCES Legal research about the national importance of immigrant profession 1 (Record only)
—
Unnecessary to the caseStatus: "Unnecessary to the case" (precisa ser "Received and valid"); Sem campos de exhibit (group order, order, title); Sem Client files e sem Translation files